Valuation: Genomma Lab Internacional, S.A.B. de C.V.

Market Cap 12.53B 707M 620M 586M 534M 999M 67.75B 1.01B 7.01B 2.72B 34.61B 2.65B 2.6B 111B P/E 2026 *
6.79x
P/E 2027 * 6.51x
Enterprise Value 16.72B 943M 828M 782M 712M 1.33B 90.4B 1.34B 9.35B 3.62B 46.18B 3.54B 3.46B 148B EV / Sales 2026 *
0.93x
EV / Sales 2027 * 0.86x
Free-Float
68.95%
Yield 2026 *
6.23%
Yield 2027 * 8.34%
1 day-0.08%
1 week+3.71%
Current month-2.65%
1 month-4.89%
3 months-14.10%
6 months-25.59%
Current year-28.17%
1 week 12.36
Extreme 12.36
12.94
1 month 12.22
Extreme 12.22
13.48
Current year 12.22
Extreme 12.22
19.48
1 year 12.22
Extreme 12.22
19.49
3 years 12.22
Extreme 12.22
29.18
5 years 12.22
Extreme 12.22
29.18
10 years 11.1
Extreme 11.1
29.18
Manager TitleAgeSince
Chief Executive Officer - 2023-04-11
Director of Finance/CFO - 2015-11-30
Investor Relations Contact - 2019-09-30
Director TitleAgeSince
Chairman - 1996-10-29
Director/Board Member - 2010-07-05
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.08%+3.71%-31.83%-7.69% 707M
+0.13%+2.65%+63.34%+115.27% 1,055B
+0.20%+0.46%+50.92%+72.63% 654B
-0.29%+0.14%+19.82%+72.62% 467B
-0.85%+0.98%+42.13%+42.98% 348B
+0.71%+4.08%+21.75%+29.57% 275B
+1.23%+0.42%+14.11%+12.90% 258B
+2.11%+7.51%+51.88%+54.14% 224B
+0.83%+0.55%+34.64%+99.77% 187B
0.00%-10.14%-27.40%-60.93% 171B
Average +0.40%+1.07%+23.94%+43.13% 363.91B
Weighted average by Cap. +0.27%+1.32%+40.41%+68.65%

Financials

2026 *2027 *
Net sales 17.99B 1.01B 891M 841M 767M 1.43B 97.28B 1.45B 10.07B 3.9B 49.7B 3.81B 3.73B 160B 18.74B 1.06B 928M 876M 798M 1.49B 101B 1.51B 10.48B 4.06B 51.77B 3.97B 3.88B 166B
Net income 1.91B 108M 94.35M 89.11M 81.21M 152M 10.31B 153M 1.07B 413M 5.26B 404M 395M 16.92B 2.06B 116M 102M 96.22M 87.69M 164M 11.13B 165M 1.15B 446M 5.68B 436M 426M 18.27B
Net Debt 4.19B 236M 207M 196M 179M 334M 22.66B 337M 2.34B 908M 11.57B 888M 868M 37.2B 3.67B 207M 181M 171M 156M 292M 19.82B 294M 2.05B 794M 10.13B 776M 760M 32.54B
Logo Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
Employees
1,658
Date Price Change Volume
26-09-25 MX$12.85 -0.08% 3,194,723
26-09-24 MX$12.86 +2.31% 4,157,460
26-09-23 MX$12.57 +0.32% 2,853,459
26-09-22 MX$12.53 +1.46% 2,718,666
26-09-21 MX$12.35 -0.32% 6,062,302
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
12.85MXN
Average target price
21.67MXN
Spread / Average Target
+68.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LAB B Stock